CN104693332A - Glycosylated medical macroporous adsorption resin - Google Patents
Glycosylated medical macroporous adsorption resin Download PDFInfo
- Publication number
- CN104693332A CN104693332A CN201410670156.0A CN201410670156A CN104693332A CN 104693332 A CN104693332 A CN 104693332A CN 201410670156 A CN201410670156 A CN 201410670156A CN 104693332 A CN104693332 A CN 104693332A
- Authority
- CN
- China
- Prior art keywords
- medical
- glycosylation
- macroporous adsorbent
- resin
- spacerarm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
The glycosylated medical macroporous adsorption resin is characterized in that a metallic element X is embedded in a skeleton carbon chain of styrene-divinylbenzene polymer resin and/or vinyl acetate-divinylbenzene polymer resin, and a glucose molecular chain is connected to the skeleton carbon chain.
Description
Technical field that the present invention belongs to:
The invention belongs to the resin absorption agent material for blood purification.
Background technology:
The present invention is an improvement project of the application number of contriver's earlier application: 201310347458.x " the new texture product of phenylethylene resin series, preparation method and its usage ".
The effect obtained clinically for the medical resin sorbent material of blood purification in prior art has caused to be paid attention to widely.Contriver invents in the medical clinical practice of ZL201110195335.x " medical macroporous adsorbent resin and application thereof " and 201310347458.x " the new texture product of phenylethylene resin series, preparation method and its usage " at existing medical macroporous adsorbent resin, find for for macromole, when particularly molecular weight reaches the especially big molecular toxicity material of 100,000 more than D and even 1,000,000 more than D, existing medical resin sorbent material is to by existing defects in the selectivity of binding molecule and adsorption rate.Major cause is in the micro-interaction force of material surface contacted between sorbent material with adsorbed material, adsorbs micro-reactive force and does not mate mutually and effectively adsorb micro-reactive force deficiency.Contriver, in the technical scheme of 201310347458.x " the new texture product of phenylethylene resin series, preparation method and its usage ", changes the skeleton structure of traditional polymeric adsorbent.Embedded in metallic element in skeleton and add avtive spot, having obvious effect to overcoming above-mentioned defect.But contriver still feels " having not given full expression to the views ".At the problem aspect that solution " in micro-interaction force, is adsorbed micro-reactive force and do not mated and effectively adsorb micro-reactive force deficiency ", also there is the space of continuing to improve.Particularly to the macromole viral material caused a disease in body, such as relate to the challenge virus albumen comprised containing genetic material, intracellular toxin macromole more than 100000 D levels, all kinds of pathogenic medium etc., still lacking can by blood purification approach, the medical polymeric adsorbent effectively they removed in body.
Summary of the invention:
The object of the invention is to propose one
the medical macroporous adsorbent resin of glycosylationtechnical scheme, in the micro-interaction force of material surface that sorbent material contacts with adsorbed material, for strengthening the micro-reactive force matching degree of absorption and strengthening the micro-reactive force of absorption, provides technology platform.
The present invention
the medical macroporous adsorbent resin of glycosylation, be embed metal X in the skeleton carbochain of styrene-divinylbenzene fluoropolymer resin and/or vinyl acetate-divinylbenzene polymer resin, and access sugar subchain in skeleton carbochain, the one performance of its molecular formula can be:
Left side dash area is the styrene-divinylbenzene fluoropolymer resin and/or the vinyl acetate-divinylbenzene polymer resin that embed metallic element X; Or:
The present invention
the medical macroporous adsorbent resin of glycosylationmaking method:
The first step: styrene-divinylbenzene fluoropolymer resin or vinyl acetate-divinylbenzene polymer resin ethanol are fully expanded;
Second step: adequately expanded resin is put into the reaction vessel that ethanol is housed, keeps ethanol liquid level higher than resin surface 10cm;
3rd step: add iron trichloride in reaction vessel, additional proportion is: resin 25kg/ iron trichloride 3kg, and reaction heats up;
4th step: add caster sugar when temperature rises to 38 degree, additional proportion is about the 1-2 of iron trichloride doubly, is advisable with 1.5 times, and Temperature fall to 30 spends positive and negative 2 degree;
5th step: heat, adds alkali (NaOH) and starts base process when temperature is risen to more than 72 degree, be warming up to reactant boiling, reaction completes.
Every data in aforementioned making method allow the error being not more than positive and negative 1/10.
Previous reaction is carried out all the time in ethanol, because glycosylation carries out in the vigorous reaction of open loop crosslinking polymerization, therefore in the structure of glycosylation resin, has also accessed ethanol molecule.Do schematically be expressed as follows glycosylated molecular formula accessing ethanol side chain:
In practice, post-crosslinking reaction process is carried out all the time in ethanol liquid, and at the end of reaction, alcohol concn becomes 30% from more than 75%, and the ethanol molecule major part lost should be enter in the molecular structure of resin, or embeds skeleton or access side chain.
Accessing in polymer molecule in the molecular formula of ethanol is a kind of schematically expression.Real situation may be the reaction process of another complexity, and ethanol molecule can be dissimilated as other molecular form and links with glycosylation molecular resin in the reaction, and embodies and have avtive spot.Contriver does not have technique means to disclose this reaction process, therefore only illustrates with this molecular formula.
The chemical reaction process of making method of the present invention:
On glycosylation resin matrix of the present invention and side chain, there is a large amount of hydrophilic hydroxyls and the phenyl ring of close ester simultaneously; Also with alkyl on ethanol side chain.Feature of the present invention is first: it has possessed parents to suction
attached power, for continuing access, there is various affine suction
attached powerfunction base, functional group and/or there is the antigen of immunosorption function, antibody provides technology platform; Secondly: it is the polymkeric substance with supramolecular volume, on the position that the molecular skeleton of overlength is different with side chain, contraposition is dispersed with the adsorption site of wetting ability or close ester, with the contact of adsorbed material in can realize compatibility very soon and adsorb, comprise structural close compatible, the attracting and surface charge of coordination different attracting; And realize multipoint adsorption for by the macromolecular substance adsorbed, certain of macromole body surface is a bit adsorbed (probability is very high), immediately can by overall Coordination Adsorption; Macromole is once would not be come off by absorption.Because the present invention is based on medical macroporous adsorbent resin, adsorbed material can enter large pore volume by the wide aperture of resin smoothly; The bigger serface of resin has more adsorption site, can adsorb more molecule.On resin matrix with alkyl can form the surface tissue with excellent blood compatibility.Selective adsorption that the present invention has, multiple spot Coordination Adsorption feature, overcoming the resin sorbent existed in prior art does not have selectivity and the low defect of adsorption rate.
According to the rear crosslinking copolymerization reaction theory of high molecular polymer, there is the high molecular polymer of tridimensional network in post-crosslinking reaction, can realize in its macromolecular carbon chain backbone, embedding metallic element, in conjunction with atoms metal in carbon atom skeleton; Also can realize accessing in resin matrix sugar subchain and ethanol molecule chain (or ethanol in complex reaction environment by recruit's chain that alienation produces).The high temperature post-crosslinking reaction that the technical program adopts, is realize embedding metallic element and access organic molecule side chain in aforementioned carbon atom skeleton, changes an invention of great significance of the high molecular polymer structure of matter.Be familiar with on a macro scale, the present invention is only a specific embodiment of this invention of great significance.Under the guidance of technical solution of the present invention, other high molecular polymer adopts the technical scheme realizing embedding metallic element and access molecular chain in its high temperature post-crosslinking reaction, all among protection scope of the present invention.
Inventive embodiment:
One of embodiment: select for endotoxic absorption ligand L
The embodiment the first step: select ligand L according to endotoxic molecular structure and surperficial affinity.
Bacterial endotoxin is also known as lipopolysaccharides, and its structure is by polysaccharide, lipid A and protein three complex body of forming of part.Intracellular toxin molecular configuration is by (glucosamine disaccharide) hydrophilic back bone and hydrophobicity long-chain fat chain, connected by tetra-sodium ester bond, final composition one has amphicheirality's slycolipid compounds of wetting ability and lipophilic (hydrophobic) property lipoid A; Wherein lipoid A is endotoxic toxicity and biological active center, and relative molecular weight is 2000d.
Carrier of the present invention has abundant hydroxyl, for " the tetra-sodium ester bond " that play link effect in intracellular toxin molecular structure, ligand L can select amino acid with amino or quadrol, amino in one end of carrier spacerarm access by chemical reaction, by the amino affine adsorption with phosphate radical, realize the selective adsorption of induced by endotoxin molecule.
Embodiment second step, the making of carrier of the present invention and endotoxin absorbent:
Carrier+spacerarm reagent (spacer arms) → carrier connects spacerarm, the other end access ligand L of carrier spacerarm.
1, spacerarm is the epoxy chloropropane of 4 carbon atom skeletons, the process of activation access " spacerarm " and ligand L, and wherein, ligand L is " amino ", and adsorption sample material is " phosphate radical ":
1.1, carrier access " spacerarm "
1.2, carrier is with spacerarm+ligand L → carrier immobilized part, that is: affinity adsorbent
1.3, affinity adsorbent compatibility adsorption sample material (sample substances, that is: S)
2, spacerarm is 1.4-hydroxyl normal butane, the bisglycidyl ether of carbon atom skeleton long chain molecule, the long process of " spacerarm " of activation access and the process of ligand L:
Embodiment the 3rd step:
Intracellular toxin is divided into endogenous intracellular toxin and exogenous intracellular toxin.Endogenous endotoxemia due to intestinal flora metabolism dysfunction or by improper approach enter body circulation cause; Exogenous inner toxemia is due to after taking antimicrobial drug, discharges to enter that body circulation causes after microorganism self-dissolving or somatic cells cracking.Adopt amphiphilic resin sorbent of the present invention, in peripheral blood extracorporeal circulation blood circuit, remove intracellular toxin by blood perfusion mode; Or enter enteron aisle by oral way, in enteron aisle, adsorb intracellular toxin toxicant, then get rid of external through digestive tube; Two kinds of modes have complementary effect.
Access the amino (NH3+1) of part and phosphate radical (PO4-3) the affine absorption on intracellular toxin molecule in sorbent molecule structure of the present invention, realize optionally adsorption effect.Due to sorbent material parents (to) property structure and endotoxic parents (to) property molecular structure can produce the avidity of compatibility simultaneously and agree with power mutually with the coordination sex appeal of surface charge and the close of molecular structure, the making a concerted effort of many kinds of force there is powerful adsorption function, show the adsorption effect obviously strengthened.And the present invention based on macroporous resin, can be detained by absorption endotoxic macromole, adsorption rate is significantly improved.
Embodiment two, for the ligand L that Other diseases is selected
The first step: access " spacerarm "
Effect: (1) provides the platform of link aglucon, for design choice absorption provides condition;
(2) in the micro-interaction force of material surface, realize the coordination of many adsorption sites, strengthen and inhale
attached power;
(3) macroporous resin can significantly improve adsorption rate.
Glycosylation copolymer resin of the present invention can as the activated rear introducing spacerarm (space arm) of carrier, the other end of resin of the present invention itself and spacerarm, can the difference in functionality base of combined belt plus or minus electric charge; The activation method that glycosylation copolymerization carrier introduces spacerarm can be von Braum reaction, can also be sodium periodate oxidation, or by the immobilized aglucon of disulfide linkage.
Spacerarm can be the epoxy chloropropane of short chain molecule; Or the 1.4-hydroxyl normal butane bisglycidyl ether of long chain molecule; Or there is short chain or the long chain molecule of similar functions group.
The other end of resin itself and spacerarm can be hydroxyl, the function base of amino or epoxy group(ing) etc. or functional group; Can with there is adsorption selection action function base or functional group as ligand L coupling, or with there is the antigen of adsorption selection effect, antibody as ligand L coupling.
Second step: access part realizes selective adsorption and multiple spot Coordination Adsorption
For the common hepatitis B by blood born, can at spacerarm one end coupling hbv antibody as ligand L, the hepatitis B antigen S in adsorption removal blood.
And for acquired immune deficiency syndrome (AIDS), can after obtaining aids antibody, using antibody coupling as ligand L, the acquired immune deficiency syndrome (AIDS) antigen S in adsorption removal blood.
The molecular chain of all high molecular weight protein virus there is amino acid group, work out corresponding base functional group, as the aglucon L of coupling on resin sorbent, the compatibility that just can realize for the amino acid group S of correspondence adsorbs, namely produce multi-point absorption simultaneously, the present invention itself has wide aperture, and macromole virus just can be trapped in body by the polymeric adsorbent of large pore volume and high-specific surface area, and removes in external.
When the viral protein molecular structure of correspondence is in confused situation, glycosylation resin of the present invention also has suitable adsorption.Such as, four evil are in the Ebola virus of the African continent, because it is also that one has bioactive prion, protein molecular section in its molecular chain must have certain seed amino acid root S, as long as the amino acid group S in corresponding Ebola virus arbitrary protein molecular section, to have the adsorbing base of compatibility as ligand L, be coupled at spacerarm one end of resin of the present invention, glycosylation resin of the present invention will produce certain site adsorption to Ebola virus; And once there is the adsorption in certain site, the powerful Coordination Adsorption of multi-point will be produced between molecular resin and viruses molecule simultaneously, macromolecular Ebola virus also can by the wide aperture of resin of the present invention, adsorbed in the vestibule of resin of the present invention, and be detained therebetween with outside purged body.
Other selective adsorption embodiment is as follows:
Ligand L is amino and hydroxyl; For adsorption removal intracellular toxin, bacterium pigment C, N,O-Diacetylmuramidase; Treatment: high endotoxemia, pyemia, septicemia, and liver failure and autoimmune disorder.
Ligand L is sulfonic group; For the acid of adsorption removal low density fat; Treatment hyperlipidemia.
Ligand L is ornithine; For adsorption removal from antibody, bile acide; Treatment liver failure, systemic lupus erythematous.
Ligand L is aldehyde radical; For adsorption removal urea, the rheumatism factor, β 2-MG; Treatment: uremia, multiple osteomyelitis, amyloidosis.
Ligand L is tryptophane; For adsorption removal AChR, antibody, Rheumatoid factors, polyclonal; Treatment: myasthenia gravis, rheumatic arthritis.
Ligand L is polyoxyethylene glycol; For the adsorption removal rheumatism factor; Treatment: rheumatic arthritis.
Ligand L is tyrosine; For adsorption removal circulating immune complex (CIC); Treatment: high CIC disease, psoriatic, bronchitis.
Ligand L is alginate calcium; For adsorbing C-VLDL (VLDL-C), low density lipoprotein cholesterol (LDV-C), lipoprotein-a (LP (a), apolipoprotein B100 (ApoB100): treatment hyperlipidaemia.
Ligand L is heparin; For adsorbing low density lipoprotein cholesterol (LDV-C); Treatment hyperlipidaemia.
Ligand L is substituted-amino; For adsorption removal immunoglobulin G (IgG), treatment barre-Guillaian syndrome.
Ligand L is vinyl cyanide; For removing neurotoxin; Treatment schizophrenia.
Ligand L is phenylalanine; For adsorption removal immunoglobulin G (IgG), treatment barre-Guillaian syndrome.
Ligand L is L-Phe; For adsorption removal immunoglobulin G (IgG), Rheumatoid factors, polyclonal; Treatment rheumatic arthritis, barre-Guillaian syndrome.。
Ligand L is Serine; For adsorption removal Rheumatoid factors, polyclonal, thyroxine, reticular tissue, single stranded deoxyribonucleic acid, double-strand anti-DNA antibody, ss-DNA; Treatment: rheumatoid arthritis, thyroiditis, scleroderma, systemic lupus erythematosus gastritis, sacred disease, autoimmune disorder.
Ligand L is urokinase; For adsorption removal uric acid; Treatment: uremia.
Ligand L is sulfuryl; For adsorption removal creatinine; Treatment uremia.
Ligand L is guanidine radicals; For adsorption removal bilirubin; Treatment hyperbilirubinemia.
Of the present invention
the medical macroporous adsorbent resin of glycosylationmay be used for filling single use blood perfusion device, is peripheral blood detoxicating.
Of the present invention
the medical macroporous adsorbent resin of glycosylationapplication mode can also be: by this resin in oral resin sorbent mode, oral do enteron aisle Disinfectant use.
Of the present invention
the medical macroporous adsorbent resin of glycosylationanother application mode be: the powder of this resin is mixed medical grade rubber, makes tube for blood transfusion,latex, purify the blood in blood-transmitted process.
Of the present invention
the medical macroporous adsorbent resin of glycosylationanother application mode be: the powder of this resin is mixed regenerated fiber,
Of the present invention
the medical macroporous adsorbent resin of glycosylationalso can use in the food industry, liquid towards food or drink carry out detoxicating.
The substantive distinguishing features that the present invention has and significant progress:
The present invention compared with prior art has outstanding substantive distinguishing features and is:
First, base resin of the present invention comprises traditional styrene-divinylbenzene three-dimensional network polymer and vinyl acetate and the three-dimensional netted multipolymer of divinylbenzene, particularly the three-dimensional netted multipolymer of vinyl acetate and divinylbenzene embeds metallic element and accesses sugar chain and ethanol chain, has wetting ability, lipotropy and excellent blood compatibility simultaneously.Embed atoms metal in carrier carbon chain backbone of the present invention, add the intensity of resin matrix, too increase the avtive spot in skeleton.
Resin of the present invention provides a technology platform, through the different technologies route of post-processed, using glycosylation resin itself or as carrier access " spacerarm ", be easy to access can with the ligand L of adsorbed material S coordination; The present invention can side chain lipotropy or hydrophilic toxicant all have fractionation by adsorption scavenging(action) to skeleton wetting ability or close ester; For each endotoxoid and toxicant, comprise the middle macromole viral protein that all kinds of inflammatory mediator, virulence factor and molecular weight occupy 100,000 grades so that 1,000,000 grades, can produce and there is the affine absorption of selective adsorption effect and/or the carrier of immunosorption.Resin sorbent of the present invention still mainly takes affine absorption principle, but its intermolecular adsorption shows as the absorption of amphiphatic multidigit point, and reactive force is significantly greater than the general affine absorption of unicity at present.The present invention in material and technical attributes, and all has outstanding substantial leap on clinical effectiveness.
The present invention compared with prior art has significant progress and is:
First, glycosylated skeleton has excellent blood compatibility through aftertreatment, can replace the glycoprotein envelope of medical resin adsorbent surface, and the quality problems that coating comes off can not occur; Secondly, glycosylation with embed metallic element in skeleton and all synchronously carry out in post-crosslinking reaction, minimizing coating process, reduces production cost.
The three-dimensional netted copolymer resin sorbent material of the vinyl acetate particularly in the present invention and divinylbenzene, adopt single stage method suspension polymerization process to produce, its technique is simple, and production cost is low; Meanwhile, not using toxic raw materials chloromethyl ether, do not pollute the environment in its polymerization process, is the desirable regeneration product of SDEB styrene diethylenebenzene polymeric adsorbent.
Claims (35)
1. the medical macroporous adsorbent resin of glycosylation, it is characterized in that: in the skeleton carbochain of styrene-divinylbenzene fluoropolymer resin and/or vinyl acetate-divinylbenzene polymer resin, embed metallic element X, and sugar subchain is accessed in skeleton carbochain, a kind of expression-form of its molecular formula can be:
2. the medical macroporous adsorbent resin of glycosylation as claimed in claim 1, it is characterized in that: in the carbochain of skeleton, access ethanol side chain, a kind of expression-form of its molecular formula can be:
3. the medical macroporous adsorbent resin of glycosylation as described in claim 1 and 2, it is characterized in that: glycosylation multipolymer is as the activated rear introducing spacerarm (space arm) of carrier, and the other end of spacerarm combines can with the difference in functionality base of plus or minus electric charge; The method of the activation method of glycosylation copolymerization carrier can be von Braum reaction, can also be sodium periodate oxidation, or by the immobilized aglucon of disulfide linkage.
4. the medical macroporous adsorbent resin of glycosylation as claimed in claim 3, is characterized in that: spacerarm can be the epoxy chloropropane of short chain molecule; Or the 1.4-hydroxyl normal butane bisglycidyl ether of long chain molecule.
5. the medical macroporous adsorbent resin of glycosylation as claimed in claim 4, is characterized in that: the other end band epoxy group(ing) of spacerarm; Epoxy group(ing) and the ligand coupling with adsorption selection effect.
6. the manufacture craft of the medical macroporous adsorbent resin of glycosylation, it is characterized in that: in post-crosslinking reaction, metal X is embedded in the skeleton carbochain of styrene-divinylbenzene fluoropolymer resin and/or vinyl acetate-divinylbenzene polymer resin, and sugar subchain is accessed in skeleton carbochain, the one of its reaction process molecular formula is expressed and can is:
7. the manufacture craft of the medical macroporous adsorbent resin of glycosylation as claimed in claim 6, is characterized in that: in post-crosslinking reaction, the carbochain of skeleton accesses ethanol side chain, and the one of its reaction process molecular formula is expressed and can is:
8. the medical macroporous adsorbent resin of glycosylation as claimed in claim 5, is characterized in that: be hbv antibody in the ligand L of spacerarm one end coupling.
9. the medical macroporous adsorbent resin of glycosylation as claimed in claim 5, is characterized in that: be aids antibody in the ligand L of spacerarm one end coupling.
10. the medical macroporous adsorbent resin of glycosylation as claimed in claim 5, is characterized in that: be the base that amino acid group S with Ebola virus in arbitrary protein molecular section has affinity in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 11. glycosylation as claimed in claim 5, is characterized in that: be amino and hydroxyl in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 12. glycosylation as claimed in claim 5, is characterized in that: be sulfonic group in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 13. glycosylation as claimed in claim 5, is characterized in that: be ornithine in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 14. glycosylation as claimed in claim 5, is characterized in that: be Pidolidone in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 15. glycosylation as claimed in claim 5, is characterized in that: be L-aldehyde radical in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 16. glycosylation as claimed in claim 5, is characterized in that: be tryptophane in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 17. glycosylation as claimed in claim 5, is characterized in that: be polyoxyethylene glycol in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 18. glycosylation as claimed in claim 5, is characterized in that: be tyrosine in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 19. glycosylation as claimed in claim 5, is characterized in that: be alginate calcium in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 20. glycosylation as claimed in claim 5, is characterized in that: be heparin in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 21. glycosylation as claimed in claim 5, is characterized in that: be substituted-amino in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 22. glycosylation as claimed in claim 5, is characterized in that: be vinyl cyanide in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 23. glycosylation as claimed in claim 5, is characterized in that: be phenylalanine in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 24. glycosylation as claimed in claim 5, is characterized in that: be aldehyde radical-CHO in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 25. glycosylation as claimed in claim 5, is characterized in that: be L-Phe in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 26. glycosylation as claimed in claim 5, is characterized in that: be Serine in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 27. glycosylation as claimed in claim 5, is characterized in that: be urokinase in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 28. glycosylation as claimed in claim 5, is characterized in that: be sulfuryl in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 29. glycosylation as claimed in claim 5, is characterized in that: be guanidine radicals in the ligand L of spacerarm one end coupling.
The medical macroporous adsorbent resin of 30. glycosylation as claimed in claim 5, is characterized in that: in the ligand L of spacerarm one end coupling be and human body endoantigen, antibody, antigen that antibody S is corresponding.
The making method of the medical macroporous adsorbent resin of 31. glycosylation as claimed in claim 1, is characterized in that:
The first step: by styrene-divinylbenzene fluoropolymer resin or vinyl acetate-divinylbenzene polymer resin ethanol fully swelling;
Second step: the reaction vessel fully swelling resin being put into dress ethanol, and keep ethanol liquid level higher than resin horizontal face 10cm;
3rd step: add iron trichloride in reaction vessel, additional proportion is: resin 25kg/ iron trichloride 3kg, and reaction heats up;
4th step: add caster sugar when temperature rises to 38 degree, additional proportion is about the 1-2 of iron trichloride doubly, is advisable, i.e. 4.5kg with 1.5 times; Temperature fall to 30 spends positive and negative 2 degree;
5th step: heat, adds alkali (NaOH) and starts base process when temperature is risen to more than 72 degree, be warming up to reactant boiling, reaction completes.
The application of 32. medical macroporous adsorbent resins of glycosylation as described in claim 1 and 2, is characterized in that: using glycosylation resin as oral resin formulation mode, for enteron aisle absorption detoxicating.
The application of 33. medical macroporous adsorbent resins of glycosylation as described in claim 1 and 2, is characterized in that: this resin sorbent powder is participated in medical silica-gel and is made into medical silicone tube, purify the blood in transfusion procedure.
The application of the medical macroporous adsorbent resin of 34. glycosylation as claimed in claim 5, is characterized in that: using glycosylation resin as oral resin formulation mode, for enteron aisle absorption detoxicating.
The application of the medical macroporous adsorbent resin of 35. glycosylation as claimed in claim 5, is characterized in that: this resin sorbent powder is participated in medical silica-gel and is made into medical silicone tube, purify the blood in transfusion procedure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410670156.0A CN104693332A (en) | 2014-10-01 | 2014-11-20 | Glycosylated medical macroporous adsorption resin |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014105231337 | 2014-10-01 | ||
| CN201410523133 | 2014-10-01 | ||
| CN201410670156.0A CN104693332A (en) | 2014-10-01 | 2014-11-20 | Glycosylated medical macroporous adsorption resin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104693332A true CN104693332A (en) | 2015-06-10 |
Family
ID=53340915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410670156.0A Withdrawn CN104693332A (en) | 2014-10-01 | 2014-11-20 | Glycosylated medical macroporous adsorption resin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104693332A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017005090A1 (en) * | 2015-07-09 | 2017-01-12 | 于杰 | Micro-nano medical adsorbent resin powder material |
| CN106362158A (en) * | 2015-07-25 | 2017-02-01 | 于杰 | Synergistic medicine |
| CN106467984A (en) * | 2015-08-19 | 2017-03-01 | 于杰 | Manufacture the chemical fibre of protecting equipment |
| CN106669630A (en) * | 2016-12-29 | 2017-05-17 | 珠海健帆生物科技股份有限公司 | Enveloped DNA immunosorbent and preparation method thereof |
| CN107432851A (en) * | 2016-05-26 | 2017-12-05 | 于杰 | The medical polymeric adsorbent Hawthorn Fruit Wine health-care bath lotion of nanoscale |
| WO2018053696A1 (en) * | 2016-09-21 | 2018-03-29 | 于杰 | Nanocarrier for treating endotoxemia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1058973A (en) * | 1990-08-16 | 1992-02-26 | 罗姆和哈斯公司 | The sorbent material that specific surface area increases |
| CN102847521A (en) * | 2011-06-28 | 2013-01-02 | 于杰 | Macro-porous adsorption resin and its application |
| CN103483487A (en) * | 2013-08-01 | 2014-01-01 | 于杰 | Novel structure product, preparation method and use of styrenic resin |
-
2014
- 2014-11-20 CN CN201410670156.0A patent/CN104693332A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1058973A (en) * | 1990-08-16 | 1992-02-26 | 罗姆和哈斯公司 | The sorbent material that specific surface area increases |
| CN102847521A (en) * | 2011-06-28 | 2013-01-02 | 于杰 | Macro-porous adsorption resin and its application |
| CN103483487A (en) * | 2013-08-01 | 2014-01-01 | 于杰 | Novel structure product, preparation method and use of styrenic resin |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017005090A1 (en) * | 2015-07-09 | 2017-01-12 | 于杰 | Micro-nano medical adsorbent resin powder material |
| JP2018522943A (en) * | 2015-07-09 | 2018-08-16 | 杰 于 | Adsorption resin powder for micro / nano medical |
| CN106362158A (en) * | 2015-07-25 | 2017-02-01 | 于杰 | Synergistic medicine |
| CN106467984A (en) * | 2015-08-19 | 2017-03-01 | 于杰 | Manufacture the chemical fibre of protecting equipment |
| CN107432851A (en) * | 2016-05-26 | 2017-12-05 | 于杰 | The medical polymeric adsorbent Hawthorn Fruit Wine health-care bath lotion of nanoscale |
| WO2018053696A1 (en) * | 2016-09-21 | 2018-03-29 | 于杰 | Nanocarrier for treating endotoxemia |
| CN106669630A (en) * | 2016-12-29 | 2017-05-17 | 珠海健帆生物科技股份有限公司 | Enveloped DNA immunosorbent and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104693332A (en) | Glycosylated medical macroporous adsorption resin | |
| EP0110409B1 (en) | Adsorbent and process for preparing the same | |
| US11826724B2 (en) | Use of a hemocompatible porous polymer bead sorbent for removal of endotoxemia-inducing molecules | |
| CN104174386B (en) | A kind of for removing the adsorbent of B2M in blood | |
| CN102614843B (en) | Protein A immunoadsorption material and preparation method thereof | |
| CN100493695C (en) | Endotoxin adsorption material for curing endotoxemia | |
| CN111250055B (en) | Chitosan-based blood perfusion adsorbent and application thereof in preparation of blood perfusion device for purifying sepsis blood | |
| Wang et al. | Nanobody-based polyvinyl alcohol beads as antifouling adsorbents for selective removal of tumor necrosis factor-α | |
| Morozov et al. | A selective sorbent for removing bacterial endotoxins from blood | |
| EP1165159B1 (en) | Oligosaccharide supports for e.g. removal of antibodies from blood | |
| CN104497193A (en) | Active vector for removing in vivo toxic substance including endotoxin in intestinal tracts | |
| JP2006288571A (en) | Adsorbent for cancer treatment and column for extracorporeal circulation | |
| CN113543821A (en) | Blood treatment device comprising alkaline phosphatase | |
| JPH0518625B2 (en) | ||
| JPS62192172A (en) | Adsorbing body | |
| JPH01119264A (en) | Adsorbent and removing device therewith | |
| JPH0611333B2 (en) | Immune complex adsorbent and immune complex removing apparatus using the same | |
| CN104403247A (en) | Blood transfusion latex tube for blood purification during blood collection in blood bank | |
| JPH0523395A (en) | Blood purifying adsorbent | |
| Beena et al. | Chitosan: A novel matrix for hemoperfusion | |
| JPH0771632B2 (en) | Adsorbent and removal device using the same | |
| Wang et al. | Recent advances in blood toxin removal technology | |
| JP3084436B2 (en) | Anti-DNA antibody removal device | |
| JPH0233265B2 (en) | ||
| CN116618024A (en) | Blood purifying adsorbent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150610 |
|
| WW01 | Invention patent application withdrawn after publication |